EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

CYTOKINE BIOMARKERS FOR THE PREDICTION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY: A COMPREHENSIVE SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS AND PRIMARY STUDIES

Muhammad Thoriq Alhabib, Namira Assyfa Nurazizah, Fikri Arif Muhammad, Chaerunnisa Auliya Putu Sugiyarti, Greatavia Meanda Leslie, Srigita Varsha, Dwi Putri Wijayanti, Fitri Nurina Septiana, Bernita Nur Cahyani, Shelda Syifa’ Azzahra, Muhamad Luthfi Asyhar, Charles Sanjaya

The International Journal of Medical Science and Health Research · 30.10.2026 · 49 (2) · 1290-1371

DOI: 10.70070/bhxfav87 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The International Journal of Medical Science and Health Research, online erschienen am 30.10.2026. Verfasst von Muhammad Thoriq Alhabib und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytokine release syndrome (CRS) remains the defining acute toxicity of chimeric antigen receptor (CAR) T-cell therapy, and the capacity to identify, before clinical deterioration, the minority of recipients who will progress to high-grade disease would allow pre-emptive rather than reactive management. Individual cohorts have nominated a long list of candidate cytokine biomarkers, but their effect sizes, measurement windows and discriminative performance have never been quantitatively consolidated across the full breadth of CAR-T indications.

Objective

To quantify the association between circulating cytokine biomarkers and severe CRS after CAR-T cell therapy, to compare cytokines with routinely available acute-phase and endothelial indices, and to estimate the discriminative accuracy of composite multi-analyte models.

Methods

The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. Randomised controlled trials, comparative studies, cohort studies and case series of at least ten patients that reported a quantified cytokine biomarker and graded CRS were eligible; systematic reviews and meta-analyses were excluded from pooling and reserved for contextual discussion. Risk of bias was appraised with ROBINS-I and Cochrane RoB 2. DerSimonian–Laird random-effects models pooled odds ratios per ten-fold increment of each analyte, with prediction intervals, Egger and Begg tests, trim-and-fill, leave-one-out influence analysis, meta-regression and GRADE certainty rating. Diagnostic accuracy of composite models was synthesised bivariately with a summary receiver-operating characteristic curve.

Results

Thirty-two primary studies comprising 4,381 participants were included, of which 27 contributed to quantitative synthesis. Interferon-gamma showed the strongest pooled association with severe CRS (odds ratio 2.65 (95% CI 2.13–3.30); I² 34%), followed by interleukin-6 (2.49 (95% CI 2.06–3.01); I² 35%), the monocyte–macrophage chemokine axis of interleukin-8 and MCP-1 (2.24 (95% CI 1.77–2.83)), interleukin-10 (2.15 (95% CI 1.78–2.60)), interleukin-2 and its soluble receptor (1.84 (95% CI 1.45–2.35)) and interleukin-15 (1.70 (95% CI 1.36–2.11)). Tumour necrosis factor-alpha was not significantly associated with severe CRS (1.18 (95% CI 0.96–1.46)). Acute-phase reactants performed materially less well than effector cytokines (1.50 (95% CI 1.30–1.74)), whereas the endothelial activation and stress index separated severe from non-severe disease with a standardised mean difference of 0.49 (95% CI 0.34–0.63). Pre-infusion composite models carried a pooled odds ratio of 2.01 (95% CI 1.70–2.38), significantly weaker than post-infusion sampling (1.60 versus 2.19; P for interaction = 0.002). Composite multi-analyte models achieved a pooled sensitivity of 77.2% (95% CI 70.5–82.7), specificity of 84.4% (79.0–88.6) and a diagnostic odds ratio of 21.0, with a mean reported area under the curve of 0.85. Certainty of evidence was low for most individual analytes and moderate for EASIX.

Conclusions

Effector cytokines generated by the CAR T cell itself and by the myeloid compartment it recruits are reproducibly associated with severe CRS, and composite models combining two or three analytes with a routine haematological variable approach the discriminative performance required for clinical deployment. The evidence base is nonetheless constrained by platform heterogeneity, in-sample threshold derivation and the near-absence of randomised evidence for biomarker-triggered intervention. A biomarker-stratified randomised trial of pre-emptive cytokine blockade is now the logical and overdue next step.

Zitieren

APA

Alhabib, M. T., Nurazizah, N. A., Muhammad, F. A., Sugiyarti, C. A. P., Leslie, G. M., Varsha, S., Wijayanti, D. P., Septiana, F. N., Cahyani, B. N., Azzahra, S. S., Asyhar, M. L., & Sanjaya, C. (2026). CYTOKINE BIOMARKERS FOR THE PREDICTION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY: A COMPREHENSIVE SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS AND PRIMARY STUDIES. The International Journal of Medical Science and Health Research, 49(2), 1290-1371. https://doi.org/10.70070/bhxfav87

Vancouver

Alhabib MT, Nurazizah NA, Muhammad FA, Sugiyarti CAP, Leslie GM, Varsha S, et al. CYTOKINE BIOMARKERS FOR THE PREDICTION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY: A COMPREHENSIVE SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS AND PRIMARY STUDIES. The International Journal of Medical Science and Health Research. 2026;49(2):1290-1371. doi:10.70070/bhxfav87

BibTeX
@article{Alhabib2026,
  author = {Alhabib, Muhammad Thoriq and Nurazizah, Namira Assyfa and Muhammad, Fikri Arif and Sugiyarti, Chaerunnisa Auliya Putu and Leslie, Greatavia Meanda and Varsha, Srigita and Wijayanti, Dwi Putri and Septiana, Fitri Nurina and Cahyani, Bernita Nur and Azzahra, Shelda Syifa’ and Asyhar, Muhamad Luthfi and Sanjaya, Charles},
  title = {CYTOKINE BIOMARKERS FOR THE PREDICTION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY: A COMPREHENSIVE SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS AND PRIMARY STUDIES},
  journal = {The International Journal of Medical Science and Health Research},
  year = {2026},
  volume = {49},
  number = {2},
  pages = {1290--1371},
  doi = {10.70070/bhxfav87}
}
Kostenlos starten →